Literature DB >> 12893095

Comorbid mood disorders and medical illness: a Food and Drug Administration perspective.

Thomas P Laughren1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12893095     DOI： 10.1016/s0006-3223(03)00529-8

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  5 in total

1.  Principles for evidence-based drug formulary policy.

Authors:  Gregory E Simon; Bruce M Psaty; Jennifer Berg Hrachovec; Marc Mora
Journal:  J Gen Intern Med       Date:  2005-10       Impact factor: 5.128

2.  Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim.

Authors:  Thomas Laughren; Robert Levin
Journal:  Schizophr Bull       Date:  2005-08-03       Impact factor: 9.306

3.  Medical problems among adolescents in U.S. mental health services: relationship to functional impairment.

Authors:  Lynn A Warner
Journal:  J Behav Health Serv Res       Date:  2006-07       Impact factor: 1.505

Review 4.  KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT?

Authors:  Samuel T Wilkinson; Gerard Sanacora
Journal:  Depress Anxiety       Date:  2016-04-15       Impact factor: 6.505

Review 5.  Measuring anxiety as a treatment endpoint in youth with autism spectrum disorder.

Authors:  Luc Lecavalier; Jeffrey J Wood; Alycia K Halladay; Nancy E Jones; Michael G Aman; Edwin H Cook; Benjamin L Handen; Bryan H King; Deborah A Pearson; Victoria Hallett; Katherine Anne Sullivan; Sabrina Grondhuis; Somer L Bishop; Joseph P Horrigan; Geraldine Dawson; Lawrence Scahill
Journal:  J Autism Dev Disord       Date:  2014-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.